| ²é¿´: 1583 | »Ø¸´: 8 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
mjjnjľ³æ (СÓÐÃûÆø)
|
[½»Á÷]
Ò»¾ä»°ÇóÖú¸ßÈË£¡¼±°¡!£¨¹ØÓÚÁÙ´²·½ÃæµÄ£¬Ó¢Ò뺺£©
|
||
| The primary efficacy endpoint was the clinical response at the test of cure (TOC) visit in the co-primary populations of the clinically evaluable (CE) and clinical modified intent-to-treat (c-mITT) patients¡£Sample Text |
» ²ÂÄãϲ»¶
0703»¯Ñ§
ÒѾÓÐ33È˻ظ´
296Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
»¯Ñ§¹¤³ÌÓë¼¼Êõרҵһ־Ը¹þ¹¤³Ì 291·ÖBÇø ¹ú¼Ò¼¶´ó´´¸ºÔðÈË ÓÐÒ»×÷ÂÛÎÄ
ÒѾÓÐ13È˻ظ´
²ÄÁÏ290µ÷¼Á
ÒѾÓÐ15È˻ظ´
368»¯Ñ§Çóµ÷¼Á
ÒѾÓÐ14È˻ظ´
µ÷¼Á
ÒѾÓÐ5È˻ظ´
Ò»Ö¾Ô¸Öйú¿ÆÑ§ÔºÉϺ£ÓлúËù£¬Óлú»¯Ñ§356·ÖÕÒµ÷¼Á
ÒѾÓÐ3È˻ظ´
Ò»Ö¾Ô¸¿ó´ó£¬²ÄÁϹ¤³Ìר˶314·Ö£¬0856¿Éµ÷¶¼¿ÉÒÔ
ÒѾÓÐ6È˻ظ´
²ÄÁÏר˶³õÊÔ·Ö332Ò»Ö¾Ô¸Î÷±±¹¤Òµ´óѧ£¬
ÒѾÓÐ6È˻ظ´
ÐÂÒ»´úµç×ÓÐÅÏ¢294Çóµ÷¼Á ²»ÌôѧУ
ÒѾÓÐ6È˻ظ´
petrocatal
ľ³æ (ÕýʽдÊÖ)
- ·ÒëEPI: 134
- Ó¦Öú: 23 (СѧÉú)
- ¹ó±ö: 0.01
- ½ð±Ò: 3436.6
- ºì»¨: 1
- Ìû×Ó: 959
- ÔÚÏß: 299.5Сʱ
- ³æºÅ: 557856
- ×¢²á: 2008-05-13
- ÐÔ±ð: GG
- רҵ: Óлú»¯¹¤

2Â¥2010-11-03 13:09:58
wust67
½ð³æ (ÖøÃûдÊÖ)
- ·ÒëEPI: 54
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ¹ó±ö: 0.005
- ½ð±Ò: 921.3
- É¢½ð: 175
- ºì»¨: 7
- Ìû×Ó: 1627
- ÔÚÏß: 339.5Сʱ
- ³æºÅ: 1009964
- ×¢²á: 2010-05-02
- רҵ: ¸ß·Ö×Ӻϳɻ¯Ñ§
3Â¥2010-11-03 13:58:57
wust67
½ð³æ (ÖøÃûдÊÖ)
- ·ÒëEPI: 54
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ¹ó±ö: 0.005
- ½ð±Ò: 921.3
- É¢½ð: 175
- ºì»¨: 7
- Ìû×Ó: 1627
- ÔÚÏß: 339.5Сʱ
- ³æºÅ: 1009964
- ×¢²á: 2010-05-02
- רҵ: ¸ß·Ö×Ӻϳɻ¯Ñ§
4Â¥2010-11-03 13:59:43
mjjnj
ľ³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 2220.4
- Ìû×Ó: 79
- ÔÚÏß: 20.9Сʱ
- ³æºÅ: 513433
- ×¢²á: 2008-02-27
- ÐÔ±ð: GG
- רҵ: ¿¹Ö×ÁöÒ©ÎïÒ©Àí
5Â¥2010-11-03 14:05:14
petrocatal
ľ³æ (ÕýʽдÊÖ)
- ·ÒëEPI: 134
- Ó¦Öú: 23 (СѧÉú)
- ¹ó±ö: 0.01
- ½ð±Ò: 3436.6
- ºì»¨: 1
- Ìû×Ó: 959
- ÔÚÏß: 299.5Сʱ
- ³æºÅ: 557856
- ×¢²á: 2008-05-13
- ÐÔ±ð: GG
- רҵ: Óлú»¯¹¤

6Â¥2010-11-03 15:17:33
mjjnj
ľ³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 2220.4
- Ìû×Ó: 79
- ÔÚÏß: 20.9Сʱ
- ³æºÅ: 513433
- ×¢²á: 2008-02-27
- ÐÔ±ð: GG
- רҵ: ¿¹Ö×ÁöÒ©ÎïÒ©Àí
| TYGACIL was evaluated in adults for the treatment of complicated skin and skin structure infections (cSSSI) in two randomized, double-blind, active-controlled, multinational, multicenter studies (Studies 300 and 305). These studies compared TYGACIL (100 mg intravenous initial dose followed by 50 mg every 12 hours) with vancomycin (1 g intravenous every 12 hours)/aztreonam (2 g intravenous every 12 hours) for 5 to 14 days. Patients with complicated deep soft tissue infections including wound infections and cellulitis (¡Ý10 cm, requiring surgery/drainage or with complicated underlying disease), major abscesses, infected ulcers, and burns were enrolled in the studies. The primary efficacy endpoint was the clinical response at the test of cure (TOC) visit in the co-primary populations of the clinically evaluable (CE) and clinical modified intent-to-treat (c-mITT) patients. See Table 6. Clinical cure rates at TOC by pathogen in the microbiologically evaluable patients are presented in Table 7. |
7Â¥2010-11-03 15:24:17
petrocatal
ľ³æ (ÕýʽдÊÖ)
- ·ÒëEPI: 134
- Ó¦Öú: 23 (СѧÉú)
- ¹ó±ö: 0.01
- ½ð±Ò: 3436.6
- ºì»¨: 1
- Ìû×Ó: 959
- ÔÚÏß: 299.5Сʱ
- ³æºÅ: 557856
- ×¢²á: 2008-05-13
- ÐÔ±ð: GG
- רҵ: Óлú»¯¹¤

8Â¥2010-11-03 21:22:52
petrocatal
ľ³æ (ÕýʽдÊÖ)
- ·ÒëEPI: 134
- Ó¦Öú: 23 (СѧÉú)
- ¹ó±ö: 0.01
- ½ð±Ò: 3436.6
- ºì»¨: 1
- Ìû×Ó: 959
- ÔÚÏß: 299.5Сʱ
- ³æºÅ: 557856
- ×¢²á: 2008-05-13
- ÐÔ±ð: GG
- רҵ: Óлú»¯¹¤

9Â¥2010-11-04 08:41:58













»Ø¸´´ËÂ¥